The prognostic utility of tests of platelet function for the detection of ‘aspirin resistance’ in patients with established cardiovascular or cerebrovascular disease: A systematic review and economic evaluation

Health Technology Assessment

Volumn 19, Issue 37, 2015, Pages 1-365

  Dretzke, Janine ^a   Riley, Richard D ^b   Lordkipanidzé, Marie ^c,d   Jowett, Susan ^a   O’Donnell, Jennifer ^a   Ensor, Joie ^b   Moloney, Eoin ^e   Price, Malcolm ^a   Raichand, Smriti ^a   Hodgkinson, James ^a   Bayliss, Susan ^a   Fitzmaurice, David ^a   Moore, David ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; THROMBOXANE B2; ANTITHROMBOCYTIC AGENT;

ADVERSE OUTCOME; ARTICLE; ASPIRIN RESISTANCE; BLEEDING; BLOOD EXAMINATION; CARDIOVASCULAR DISEASE; CELL COUNTER; CEREBROVASCULAR DISEASE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG RESISTANCE; ECONOMIC EVALUATION; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; MONOTHERAPY; MORTALITY; PLATELET AGGREGATION ASSAY; PREDICTION; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; SECONDARY PREVENTION; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; THROMBOELASTOGRAPH; THROMBOELASTOGRAPHY; THROMBOSIS; WHOLE BLOOD AGGREGOMETRY; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; COST BENEFIT ANALYSIS; DEVICES; ECONOMICS; RISK FACTOR;

ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROGNOSIS; RISK FACTORS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; THROMBOSIS;

EID: 84929404968     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta19370     Document Type: Article

References (308)

1. Scarborough P, Bhatnagar P, Wickramasinghe K, Smolina K, Mitchell C, Rayner M. Coronary Heart Disease Statistics 2010. 2010 edn. London: British Heart Foundation; 2010.
2. Jack DB. One hundred years of aspirin. Lancet 1997;350:437–9. http://dx.doi.org/10.1016/S0140-6736(97)07087-6
3. Health and Social Care Information Centre, Prescribing and Primary Care Services. Prescriptions Dispensed in the Community: England, Statistics for 2001 to 2011. Leeds: Health and Social Care Information Centre; 2011.
4. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849–60. http://dx.doi.org/10.1016/S0140-6736(09)60503-1
5. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl. 2):e89–119.
6. Bell AD, Roussin A, Cartier R, Chan WS, Douketis JD, Gupta A, et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can J Cardiol 2011;27:208–21. http://dx.doi.org/10.1016/j.cjca.2010.12.033
7. American Diabetes Association. Standards of medical care in diabetes – 2013. Diabetes Care 2013;36(Suppl. 1):11–66. http://dx.doi.org/10.2337/dc13-S011
8. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010;33:1395–402. http://dx.doi.org/10.2337/dc10-0555
9. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010;9:154–69. http://dx.doi.org/10.1038/nrd2957
10. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation 2010;121:e46–215. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192667
11. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:517–84. http://dx.doi.org/10.1161/STR.0b013e3181fcb238
12. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg 2007;45:1185–91. http://dx.doi.org/10.1016/j.jvs.2007.02.004
13. Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clement D, Collet JP, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2851–906. http://dx.doi.org/10.1093/eurheartj/ehr211
14. Lordkipanidzé M. Advances in monitoring of aspirin therapy. Platelets 2012;23:526–36. http://dx.doi.org/10.3109/09537104.2012.711865
15. Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206–18. http://dx.doi.org/10.1161/01.CIR.101.10.1206
16. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232–5. http://dx.doi.org/10.1038/newbio231232a0
17. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:624–32. http://dx.doi.org/10.1172/JCI108132
18. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366–72. http://dx.doi.org/10.1172/JCI110576
19. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin – what’s the risk? Aliment Pharmacol Ther 2006;24:897–908. http://dx.doi.org/10.1111/j.1365-2036.2006.03077.x
20. Bertrand OF, Larose E, Rodes-Cabau J, Gleeton O, Taillon I, Roy L, et al. Incidence, predictors, and clinical impact of bleeding after transradial coronary stenting and maximal antiplatelet therapy. Am Heart J 2009;157:164–9. http://dx.doi.org/10.1016/j.ahj.2008.09.010
21. Suh JW, Mehran R, Claessen BE, Xu K, Baber U, Dangas G, et al. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction)trial. J Am Coll Cardiol 2011;58:1750–6. http://dx.doi.org/10.1016/j.jacc.2011.07.021
22. Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011;32:2922–32. http://dx.doi.org/10.1093/eurheartj/ehr373
23. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS)in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999–3054. http://dx.doi.org/10.1093/eurheartj/ehr236
24. Smith SC, Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124:2458–73. http://dx.doi.org/10.1161/CIR.0b013e318235eb4d
25. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE, Jr, Ettinger SM, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:2022–60. http://dx.doi.org/10.1161/CIR.0b013e31820f2f3e
26. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501–55. http://dx.doi.org/10.1093/eurheartj/ehq277
27. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124:e574–651. http://dx.doi.org/10.1161/CIR.0b013e31823ba622
28. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3:1309–11. http://dx.doi.org/10.1111/j.1538-7836.2005.01351.x
29. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980–7. http://dx.doi.org/10.1161/01.ATV.0000145980.39477.a9
30. European Agency for the Evaluation of Medicinal Products. Position Paper on the Regulatory Requirements for the Authorization of Low-Dose Modified Release ASA Formulations in the Secondary Prevention of Cardiovascular Events. London: European Medicines Agency; 2002.
31. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 2008;118:18–35. http://dx.doi.org/10.1016/j.pharmthera.2008.01.001
32. Grove EL, Storey RF, Wurtz M. Platelet function testing in atherothrombotic disease. Curr Pharm Des 2012;18:5379–91. http://dx.doi.org/10.2174/138161212803251862
33. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991;68:11B–15B. http://dx.doi.org/10.1016/0002-9149(91)90379-Y
34. Crescente M, Di Castelnuovo A, Iacoviello L, De Gaetano G, Cerletti C. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients. Thromb Haemost 2008;99:1129–31. http://dx.doi.org/10.1160/TH08-03-0130
35. Chan MV, Armstrong PC, Papalia F, Kirkby NS, Warner TD. Optical multichannel (optimul)platelet aggregometry in 96-well plates as an additional method of platelet reactivity testing. Platelets 2011;22:485–94. http://dx.doi.org/10.3109/09537104.2011.592958
36. Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin ‘resistance’. J Am Coll Cardiol 2009;53:667–77. http://dx.doi.org/10.1016/j.jacc.2008.10.047
37. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702–8. http://dx.doi.org/10.1093/eurheartj/ehm226
38. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005;46:1705–9. http://dx.doi.org/10.1016/j.jacc.2005.05.090
39. Gurbel PA, Bliden KP, Dichiara J, Newcomer J, Weng W, Neerchal NK, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT)study. Circulation 2007;115:3156–64. http://dx.doi.org/10.1161/CIRCULATIONAHA.
40. Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007;115:2490–6. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.667584
41. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005;36:1001–5. http://dx.doi.org/10.1161/01.STR.0000162719.11058.bd
42. Frelinger AL III, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1-and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006;113:2888–96. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.596627
43. Rocca B, Petrucci G. Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms. Thrombosis 2012;2012:376721. http://dx.doi.org/10.1155/2012/376721
44. Lordkipanidzé M, Pharand C, Palisaitis DA, Diodati JG. Aspirin resistance: truth or dare. Pharmacol Ther 2006;112:733–43. http://dx.doi.org/10.1016/j.pharmthera.2006.05.011
45. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005;95:973–5. http://dx.doi.org/10.1016/j.amjcard.2004.12.038
46. Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004;147:293–300. http://dx.doi.org/10.1016/j.ahj.2003.07.011
47. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231–43. http://dx.doi.org/10.1016/S0140-6736(11)61215-4
48. Peace A, McCall M, Tedesco T, Kenny D, Conroy RM, Foley D, et al. The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost 2010;8:2323–5. http://dx.doi.org/10.1111/j.1538-7836.2010.03997.x
49. Katona E, Kovacs E, Bereczky Z, Balogh L, Homorodi N, Haramura G, et al. Development of reference methods for evaluating the effect of aspirin and for comparison with routinely used methods; the lack of aspirin resistance in healthy volunteers. J Thromb Haemost 2011;9:15–19.
50. Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med 2008;6:46. http://dx.doi.org/10.1186/1479-5876-6-46
51. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809–17. http://dx.doi.org/10.1056/NEJMoa003199
52. Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005;45:1295–1301. http://dx.doi.org/10.1016/j.jacc.2005.01.045
53. Wilner KD, Rushing M, Walden C, Adler R, Eskra J, Noveck R, et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol 2002;42:1027–30. http://dx.doi.org/10.1177/009127002401102858
54. Van Ryn J, Kink-Eiband M, Kuritsch I, Feifel U, Hanft G, Wallenstein G, et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 2004;44:777–84. http://dx.doi.org/10.1177/0091270004266623
55. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005;46:1258–63. http://dx.doi.org/10.1016/j.jacc.2005.06.058
56. Angiolillo DJ. Antiplatelet therapy in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007;14:124–31. http://dx.doi.org/10.1097/MED.0b013e32807f2ad9
57. Dichiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT)study. Diabetes 2007;56:3014–19. http://dx.doi.org/10.2337/db07-0707
58. Watala C, Boncler M, Gresner P. Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 2005;57(Suppl.):42–58.
59. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)– its relation to metabolic control. Thromb Res 2004;113:101–13. http://dx.doi.org/10.1016/j.thromres.2003.12.016
60. Pulcinelli FM, Biasucci LM, Riondino S, Giubilato S, Leo A, Di Renzo L, et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J 2009;30:1279–86. http://dx.doi.org/10.1093/eurheartj/ehp097
61. Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z, et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med (Berl) 2005;83:148–58. http://dx.doi.org/10.1007/s00109-004-0600-x
62. Kobzar G, Mardla V, Samel N. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors. Platelets 2011;22:338–44. http://dx.doi.org/10.3109/09537104.2010.535931
63. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595–603. http://dx.doi.org/10.1182/blood-2011-06-359224
64. Dillinger JG, Sideris G, Henry P, Bal dit Sollier C, Ronez E, Drouet L. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia. Thromb Res 2012;129:91–4. http://dx.doi.org/10.1016/j.thromres.2011.09.017
65. Dragani A, Pascale S, Recchiuti A, Mattoscio D, Lattanzio S, Petrucci G, et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 2010;115:1054–61. http://dx.doi.org/10.1182/blood-2009-08-236679
66. Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger JG, et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011;105:336–44. http://dx.doi.org/10.1160/TH10-02-0082
67. Lordkipanidzé M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Int J Cardiol 2011;150:39–44. http://dx.doi.org/10.1016/j.ijcard.2010.02.025
68. Perneby C, Wallen NH, Rooney C, Fitzgerald D, Hjemdahl P. Dose-and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006;95:652–8.
69. Di Minno G. Aspirin resistance and platelet turnover: a 25-year old issue. Nutr Metab Cardiovasc Dis 2011;21:542–5. http://dx.doi.org/10.1016/j.numecd.2011.04.002
70. Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011;9:185–91. http://dx.doi.org/10.1111/j.1538-7836.2010.04115.x
71. Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011;4:180–7. http://dx.doi.org/10.1161/CIRCINTERVENTIONS.110.960187
72. Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012;10:1220–30. http://dx.doi.org/10.1111/j.1538-7836.2012.04723.x
73. Spectre G, Arnetz L, Ostenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro-or macrovascular complications. Thromb Haemost 2011;106:491–9. http://dx.doi.org/10.1160/TH11-04-0216
74. Wurtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des 2012;18:5344–61. http://dx.doi.org/10.2174/138161212803251925
75. Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010;103:1245–53. http://dx.doi.org/10.1160/TH09-08-0527
76. Frelinger AL III, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009;120:2586–96. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.900589
77. Cattaneo M. Laboratory detection of ‘aspirin resistance’: what test should we use (if any)? Eur Heart J 2007;28:1673–5. http://dx.doi.org/10.1093/eurheartj/ehm232
78. Raichand S, Moore D, Riley R, Lordkipanidzé M, Dretzke J, O’Donnell J, et al. Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease. Syst Rev 2013;2:16. http://dx.doi.org/10.1186/2046-4053-2-16
79. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36. http://dx.doi.org/10.7326/0003-4819-155-8-201110180-00009
80. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144:427–37. http://dx.doi.org/10.7326/0003-4819-144-6-200603210-00010
81. Altman DG. Prognostic models: a methodological framework and review of models for breast cancer. Cancer Invest 2009;27:235–43. http://dx.doi.org/10.1080/07357900802572110
82. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815–34. http://dx.doi.org/10.1002/(SICI)1097-0258(19981230)17:24%3C2815::AID-SIM110%3E3.0.CO;2-8
83. Perneger TV. Estimating the relative hazard by the ratio of logarithms of event-free proportions. Contemp Clin Trials 2008;29:762–6. http://dx.doi.org/10.1016/j.cct.2008.06.002
84. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351–75. http://dx.doi.org/10.1002/sim.1761
85. Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol 2008;51:701–7. http://dx.doi.org/10.1016/j.jacc.2007.10.034
86. Ozben S, Ozben B, Tanrikulu AM, Ozer F, Ozben T. Aspirin resistance in patients with acute ischemic stroke. J Neurol 2011;258:1979–86. http://dx.doi.org/10.1007/s00415-011-6052-7
87. Lee SP, Park KW, Shin DH, Lee HY, Kang HJ, Koo BK, et al. Efficacy of predicting thrombotic events with combination of dual point-of-care testing (POCT)after drug-eluting stent implantation for coronary heart disease: results from the CILON-T randomized trial POCT substudy. J Atheroscler Thromb 2011;18:914–23. http://dx.doi.org/10.5551/jat.9290
88. Feher A, Pusch G, Harang G, Gasztonyi B, Papp E, Werling D, et al. Aspirin resistance in cerebrovascular patients. Int J Cardiol 2011;152:111–12. http://dx.doi.org/10.1016/j.ijcard.2011.07.028
89. Chiu FC, Wang TD, Lee JK, Shih FY, Lin JW, Huang CH, et al. Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention. Eur J Intern Med 2011;22:471–7. http://dx.doi.org/10.1016/j.ejim.2011.02.021
90. van der Loo B, Braun J, Koppensteiner R. On-treatment function testing of platelets and long-term outcome of patients with peripheral arterial disease undergoing transluminal angioplasty. Eur J Vasc Endovasc Surg 2011;42:809–16. http://dx.doi.org/10.1016/j.ejvs.2011.08.014
91. Amoah V, Smallwood A, Worrall AP, Lovatt T, Armesilla AL, Nevill AM, et al. Poor aspirin response in diabetic patients presenting with acute coronary syndromes: results using a near patient test. Thromb Res 2011;128:196–9. http://dx.doi.org/10.1016/j.thromres.2011.04.003
92. Kim HJ, Lee JM, Seo JH, Kim JH, Hong DM, Bahk JH, et al. Preoperative aspirin resistance does not increase myocardial injury during off-pump coronary artery bypass surgery. J Korean Med Sci 2011;26:1041–6. http://dx.doi.org/10.3346/jkms.2011.26.8.1041
93. Spectre G, Mosseri M, Abdelrahman NM, Briskin E, Bulut A, Loncar S, et al. Clinical and prognostic implications of the initial response to aspirin in patients with acute coronary syndrome. Am J Cardiol 2011;108:1112–18. http://dx.doi.org/10.1016/j.amjcard.2011.06.013
94. Grdinic A, Vojvodic D, Djukanovic N, Colic M, Grdinic AG, Ignjatovic V, et al. PCI and clopidogrel: antiplatelet responsiveness and patient characteristics. Acta Cardiol 2011;66:333–40.
95. Abumiya T, Houkin K. Association of recurrent cerebral infarction with adenosine diphosphate-and collagen-induced platelet aggregation in patients treated with ticlopidine and/or aspirin. J Stroke Cerebrovasc Dis 2011;20:319–23. http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2010.01.013
96. Angiolillo DJ, Bernardo E, Zanoni M, Vivas D, Capranzano P, Malerba G, et al. Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2011;58:30–9. http://dx.doi.org/10.1016/j.jacc.2011.02.040
97. Kuliczkowski W, Greif M, Gasior M, Kaczmarski J, Pres D, Polonski L. Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Kardiol Pol 2011;69:531–7.
98. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Harmsze AM, Hackeng CM, et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011;97:983–90. http://dx.doi.org/10.1136/hrt.2010.220491
99. Gluckman TJ, McLean RC, Schulman SP, Kickler TS, Shapiro EP, Conte JV, et al. Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol 2011;57:1069–77. http://dx.doi.org/10.1016/j.jacc.2010.08.650
100. Ko YG, Suh JW, Kim BH, Lee CJ, Kim JS, Choi D, et al. Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart J 2011;161:383–90. http://dx.doi.org/10.1016/j.ahj.2010.10.036
101. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, ten Berg JM, Hackeng CM. High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 2010;8:2140–8. http://dx.doi.org/10.1111/j.1538-7836.2010.04017.x
102. Smit JJ, van Werkum JW, ten Berg J, Slingerland R, Ottervanger JP, Heestermans T, et al. Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy. Heart 2010;96:1815–20. http://dx.doi.org/10.1136/hrt.2010.201889
103. Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel)trial substudy. J Am Coll Cardiol 2010;56:1447–55. http://dx.doi.org/10.1016/j.jacc.2010.03.103
104. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, et al. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 2010;104:279–86. http://dx.doi.org/10.1160/TH10-01-0007
105. Chu JW, Wong CK, Chambers J, Wout JV, Herbison P, Tang EW. Aspirin resistance determined from a bed-side test in patients suspected to have acute coronary syndrome portends a worse 6 months outcome. QJM 2010;103:405–12. http://dx.doi.org/10.1093/qjmed/hcq038
106. Eshtehardi P, Windecker S, Cook S, Billinger M, Togni M, Garachemani A, et al. Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. Am Heart J 2010;159:891–8. http://dx.doi.org/10.1016/j.ahj.2010.02.025
107. Campo G, Valgimigli M, Frangione A, Luccarelli S, Cangiano E, Cavazza C, et al. Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel). J Am Coll Cardiol 2010;55:255–6. http://dx.doi.org/10.1016/j.jacc.2009.08.052
108. Addad F, Chakroun T, Abderazek F, Ben-Farhat M, Hamdi S, Dridi Z, et al. Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease. J Thromb Thrombolysis 2010;29:108–13. http://dx.doi.org/10.1007/s11239-009-0335-1
109. Aksu H, Ozer O, Unal H, Hobikoglu G, Norgaz T, Buturak A, et al. Significance of mean platelet volume on prognosis of patients with and without aspirin resistance in settings of non-ST-segment elevated acute coronary syndromes. Blood Coagul Fibrinolysis 2009;20:686–93. http://dx.doi.org/10.1097/MBC.0b013e32833161ac
110. Thomson VS, John B, George P, Joseph G, Jose J. Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events. J Postgrad Med 2009;55:252–6. http://dx.doi.org/10.4103/0022-3859.58927
111. Cuisset T, Cayla G, Frere C, Quilici J, Poyet R, Gaborit B, et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? Eurointervention 2009;5:325–9. http://dx.doi.org/10.4244/51
112. Linnemann B, Prochnow S, Mani H, Schwonberg J, Lindhoff-Last E. Variability of non-response to aspirin in patients with peripheral arterial occlusive disease during long-term follow-up. Ann Hematol 2009;88:979–88. http://dx.doi.org/10.1007/s00277-009-0708-8
113. Kempfert J, Anger K, Rastan A, Krabbes S, Lehmann S, Garbade J, et al. Postoperative development of aspirin resistance following coronary artery bypass. Eur J Clin Invest 2009;39:769–74. http://dx.doi.org/10.1111/j.1365-2362.2009.02175.x
114. Ivandic BT, Sausemuth M, Ibrahim H, Giannitsis E, Gawaz M, Katus HA. Dual antiplatelet drug resistance is a risk factor for cardiovascular events after percutaneous coronary intervention. Clin Chem 2009;55:1171–6. http://dx.doi.org/10.1373/clinchem.2008.115089
115. Foussas SG, Zairis MN, Tsirimpis VG, Makrygiannis SS, Patsourakos NG, Adamopoulou EN, et al. The impact of aspirin resistance on the long-term cardiovascular mortality in patients with non-ST segment elevation acute coronary syndromes. Clin Cardiol 2009;32:142–7. http://dx.doi.org/10.1002/clc.20293
116. Boncoraglio GB, Bodini A, Brambilla C, Corsini E, Carriero MR, Parati EA. Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease. Clin Neurol Neurosurg 2009;111:270–3. http://dx.doi.org/10.1016/j.clineuro.2008.11.001
117. Majeed F, Kop WJ, Poston RS, Kallam S, Mehra MR. Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices. Nat Clin Pract Cardiovasc Med 2009;6:147–57. http://dx.doi.org/10.1038/ncpcardio1441
118. Bevilacqua S, Alkodami AA, Volpi E, Cerillo AG, Berti S, Glauber M, et al. Risk stratification after coronary artery bypass surgery by a point-of-care test of platelet function. Ann Thorac Surg 2009;87:496–502. http://dx.doi.org/10.1016/j.athoracsur.2008.05.038
119. Saw J, Densem C, Walsh S, Jokhi P, Starovoytov A, Fox R, et al. The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention)trial substudy. JACC Cardiovasc Interv 2008;1:654–9. http://dx.doi.org/10.1016/j.jcin.2008.08.017
120. Gori AM, Marcucci R, Paniccia R, Giusti B, Fedi S, Antonucci E, et al. Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. Thromb Haemost 2008;100:1136–45.
121. Cha JK, Jeon HW, Kang MJ. ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. Eur J Neurol 2008;15:1304–8. http://dx.doi.org/10.1111/j.1468-1331.2008.02306.x
122. Gurbel PA, Antonino MJ, Bliden KP, Dichiara J, Suarez TA, Singla A, et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 2008;19:595–604. http://dx.doi.org/10.1080/09537100802351065
123. Campo G, Valgimigli M, Frangione A, Tebaldi M, Ferrari R. Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI. J Thromb Haemost 2008;6:1824–6. http://dx.doi.org/10.1111/j.1538-7836.2008.03112.x
124. Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008;52:734–9. http://dx.doi.org/10.1016/j.jacc.2008.05.032
125. Schwammenthal Y, Tsabari R, Shenkman B, Schwartz R, Matetzky S, Lubetsky A, et al. Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome. Cerebrovasc Dis 2008;25:355–61. http://dx.doi.org/10.1159/000118382
126. Aradi D, Konyi A, Palinkas L, Berki T, Pinter T, Tahin T, et al. Thienopyridine therapy influences late outcome after coronary stent implantation. Angiology 2008;59:172–8. http://dx.doi.org/10.1177/0003319707304572
127. Christiaens L, Ragot S, Mergy J, Allal J, Macchi L. Major clinical vascular events and aspirinresistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. Blood Coagul Fibrinolysis 2008;19:235–9. http://dx.doi.org/10.1097/MBC.0b013e3282f9ade8
128. Gengo FM, Rainka M, Robson M, Gengo MF, Forrest A, Hourihane M, et al. Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. J Clin Pharmacol 2008;48:335–43. http://dx.doi.org/10.1177/0091270007313324
129. Jacopo G, Elisabetta V, Silverio S, Massimiliano M, Sergio B, Grazia AM, et al. Identification of platelet hyper-reactivity measured with a portable device immediately after percutaneous coronary intervention predicts in stent thrombosis. Thromb Res 2007;121:407–12. http://dx.doi.org/10.1016/j.thromres.2007.04.009
130. Blindt R, Stellbrink K, de Taeye A, Muller R, Kiefer P, Yagmur E, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007;98:1329–34.
131. Foussas SG, Zairis MN, Patsourakos NG, Makrygiannis SS, Adamopoulou EN, Handanis SM, et al. The impact of oral antiplatelet responsiveness on the long-term prognosis after coronary stenting. Am Heart J 2007;154:676–81. http://dx.doi.org/10.1016/j.ahj.2007.06.013
132. Poulsen TS, Kristensen SR, Korsholm L, Haghfelt T, Jorgensen B, Licht PB, et al. Variation and importance of aspirin resistance in patients with known cardiovascular disease. Thromb Res 2007;120:477–84. http://dx.doi.org/10.1016/j.thromres.2006.10.022
133. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007;120:631–5. http://dx.doi.org/10.1016/j.amjmed.2006.10.021
134. Buch AN, Singh S, Roy P, Javaid A, Smith KA, George CE, et al. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007;99:1518–22. http://dx.doi.org/10.1016/j.amjcard.2007.01.023
135. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Destegul E, et al. The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol 2007;23:201–6. http://dx.doi.org/10.1016/S0828-282X(07)70744-4
136. Bliden KP, Dichiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49:657–66. http://dx.doi.org/10.1016/j.jacc.2006.10.050
137. Pamukcu B, Oflaz H, Onur I, Oncul A, Ozcan M, Umman B, et al. Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). Blood Coagul Fibrinolysis 2007;18:187–92. http://dx.doi.org/10.1097/MBC.0b013e328040c115
138. Fuchs I, Frossard M, Spiel A, Riedmuller E, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS)predicts recurrent ACS. J Thromb Haemost 2006;4:2547–52. http://dx.doi.org/10.1111/j.1538-7836.2006.02239.x
139. Marcucci R, Paniccia R, Antonucci E, Gori AM, Fedi S, Giglioli C, et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol 2006;98:1156–9. http://dx.doi.org/10.1016/j.amjcard.2006.05.041
140. Pamukcu B, Oflaz H, Oncul A, Umman B, Mercanoglu F, Ozcan M, et al. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J Thromb Thrombolysis 2006;22:103–10. http://dx.doi.org/10.1007/s11239-006-8952-4
141. Gianetti J, Parri MS, Sbrana S, Paoli F, Maffei S, Paradossi U, et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb Res 2006;118:487–93. http://dx.doi.org/10.1016/j.thromres.2005.10.011
142. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s)in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006;4:1271–8. http://dx.doi.org/10.1111/j.1538-7836.2006.01958.x
143. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542–9. http://dx.doi.org/10.1111/j.1538-7836.2005.01751.x
144. Morawski W, Sanak M, Cisowski M, Szczeklik M, Szczeklik W, Dropinski J, et al. Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. J Thorac Cardiovasc Surg 2005;130:791–6. http://dx.doi.org/10.1016/j.jtcvs.2005.02.041
145. Sambola A, Heras M, Escolar G, Lozano M, Pino M, Martorell T, et al. The PFA-100 detects sub-optimal antiplatelet responses in patients on aspirin. Platelets 2004;15:439–46. http://dx.doi.org/10.1080/69537100412351272550
146. Stejskal D, Proskova J, Lacnak B, Horalik D, Hamplova A, Oral I, et al. [Use of assessment of aggregation of thrombocytes induced by cationic propyl gallate to estimate recurrence of cardiovascular complications.] Vnitr Lek 2004;50:591–9.
147. Payne DA, Jones CI, Hayes PD, Thompson MM, London NJ, Bell PR, et al. Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy. Circulation 2004;109:1476–81. http://dx.doi.org/10.1161/01.CIR.0000121739.05643.E6
148. Bruno A, McConnell JP, Cohen SN, Tietjen GE, Wallis RA, Gorelick PB, et al. Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. Stroke 2004;35:727–30. http://dx.doi.org/10.1161/01.STR.0000117097.76953.A6
149. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961–5. [Erratum published in J Am Coll Cardiol 2006;48:1918.] http://dx.doi.org/10.1016/S0735-1097(02)03014-0
150. Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 2002;13:493–7. http://dx.doi.org/10.1080/0953710021000057866
151. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650–5. http://dx.doi.org/10.1161/01.CIR.0000013777.21160.07
152. Buchanan MR, Schwartz L, Bourassa M, Brister SJ, Peniston CM; BRAT Investigators. Results of the BRAT study – a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 2000;16:1385–90.
153. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003–7.
154. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397–403. http://dx.doi.org/10.1016/0049-3848(93)90164-J
155. Sørensen PS, Agerskov AL, Gormsen J, Pedersen H, Marquardsen J, Petersson H, et al. Prognostic value of in vitro measurements of platelet aggregability and fibrinolytic activity in patients with reversible cerebral ischemic attacks. Eur Neurol 1983;22:437–41. http://dx.doi.org/10.1159/000115599
156. Tang FK, Lin LJ, Hua N, Lu H, Qi Z, Tang XZ. Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention. Chin Med J 2012;125:631–8.
157. Breet NJ, Sluman MA, van Berkel MAJPJ, van Werkum JW, Bouman HJ, Harmsze AM, et al. Effect of gender difference on platelet reactivity. Neth Heart J 2011;19:451–7. http://dx.doi.org/10.1007/s12471-011-0189-y
158. Milicic D, Lovric D, Skoric B, Narancic-Skoric K, Gornik I, Sertic J. Platelet response to standard aspirin and clopidogrel treatment correlates with long-term outcome in patients with acute ST-elevation myocardial infarction. Int J Cardiol 2011;153:227–9. http://dx.doi.org/10.1016/j.ijcard.2011.09.055
159. De Boni A, De Riva V, Galloni E, Perini F. Residual platelet activity and clinical failure of antithrombotic prophylaxis in acute cerebral ischaemic stroke. Riv Ital Med Labor 2011;7:163–9. http://dx.doi.org/10.1007/s13631-011-0024-8
160. Marcucci R, Gori AM, Paniccia R, Giusti B, Cordisco A, Balzi D, et al. High-on treatment platelet reactivity by different stimuli is a determinant of 1 year mortality in acute coronary syndrome patients: Data from AMI-florence 2 study. J Thromb Haemost 2011;9:546–7.
161. Marcucci R, Gori AM, Paniccia R, Giusti B, Cordisco A, Balzi D, et al. High-on clopidogrel platelet reactivity is a determinant of 1-year mortality in acute coronary syndrome patients: Data from AMI-florence 2 study. J Thromb Haemost 2011;9:546.
162. Lordkipanidzé M, Diodati JG, Schampaert E, Palisaitis DA, Pharand C. Lack of clinical predictiveness of six major platelet function tests used to assess aspirin response in patients with stable coronary artery disease. J Thromb Haemost 2011;9:343.
163. Spectre G, Mosseri M, Abdelrahman NM, Briskin E, Bulut A, Loncar S, et al. Dynamic response to aspirin in patients with acute coronary syndrome, clinical and prognostic implications. J Thromb Haemost 2011;9:338. http://dx.doi.org/10.1016/j.amjcard.2011.06.013
164. Miyata S, Kada A, Nagatsuka K. Clinical impact of aspirin ‘resistance’ on the secondary prevention of atherothrombosis. J Thromb Haemost 2011;9:257.
165. Kaymaz C, Tokgoz HC, Tanboga IH, Poci N, Aktemur T, Kirca N, et al. Can we translate the high and low on-treatment platelet reactivity to early, mid and long term risks for ischemic and bleeding events following the stent placement. Eur Heart J 2011;32:755.
166. Orta KK, Kocas C, Yildiz A, Abaci O, Okcun B, Coskun U, et al. Long-term follow-up of the patients with Aspirin resistant end stage kidney disease. Eur Heart J 2011;32:322–3.
167. Kaymaz C, Tanboga IH, Tokgoz HC, Can MM, Poci N, Aktemur T, et al. Comparison of multiplate, VerifyNow and PFA-100 in the assessment of on-treatment platelet reactivity in patients treated with aspirin and clopidogrel following coronary stenting. Eur Heart J 2011;32:246.
168. Sahin DY, Koc M, Cayli M, Sen O, Kalkan GY, Kanadasi M, et al. Frequency of aspirin resistance in patients with chronic ischemic heart disease in Cukurova region and the relationship between aspirin resistance and adverse clinical events. Int J Cardiol 2011;147:S157. http://dx.doi.org/10.1016/S0167-5273(11)70427-2
169. Zanow J, Eckart A, Ludewig S, Losche W. Frequency and clinical significance of the ‘non-response’ to acetylsalicylic acid in patients with peripheral occlusive artery disease. Vasomed 2010;22:277.
170. Ryu D-S, Hong C-K, Sim Y-S, Kim C-H, Jung J-Y, Joo J-Y. Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention. J Korean Neurosurg Soc 2010;48:319–24. http://dx.doi.org/10.3340/jkns.2010.48.4.319
171. Lee J-H, Cha J-K, Lee SJ, Ha S-W, Kwon SU. Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. Eur J Neurol 2010;17:434–42. http://dx.doi.org/10.1111/j.1468-1331.2009.02837.x
172. Angiolillo D, Bernardo E, Zanoni M, Capranzano P, Malerba G, Trabetti E, et al. Impact of IRS-1 genotypes on platelet reactivity and cardiovascular outcomes in type 2 diabetes mellitus patients with coronary artery disease. J Am Coll Cardiol 2010;55(Suppl. 1):A207. http://dx.doi.org/10.1016/j.jacc.2011.02.040
173. Bouman HJ, van Werkum JW, Smit JJ, Breet NJ, Postma S, Heestermans T, et al. Predictive value of various platelet function tests on ST-segment resolution and clinical outcome in stemi patients randomized to either dual or triple antiplatelet therapy: the onTIME2 platelet function substudy. J Am Coll Cardiol 2010;55(Suppl. 1):A207. http://dx.doi.org/10.1016/S0735-1097(10)61949-3
174. Tan C, Lin J, Chen W, Lin R, Chen S. Elevated serum ubiquitin and ubiquitin conjugates: A potential biomarker for aspirin resistance in acute myocardial infarction patients. Arterioscler Thromb Vasc Biol 2010;30:e219–20.
175. Toth G, Pride GL, Novakovic R, Matevosyan K, Sarode R, Welch BG. Thromboembolic complications and response to antiplatelet therapy in patients undergoing endovascular stenting for aneurysm treatment. Stroke 2010;41:e265–6.
176. Bobesc E, Rado M, Datc G, Dobrean D, Dok BF. The effects of endothelial dysfunction, platelets hyperactivity, oxidative stress biomarkers on ejection fraction, wall motion score index and prognosis in patients with acute coronary syndromes. Eur J Echocardiogr 2010;11:ii122–3.
177. Bobescu E, Radoi M, Datcu G, Dobreanu D, Doka B. Correlation between endothelial dysfunction, platelets hyperactivity, oxidative stress biomarkers and cumulative effects on prognosis in patients with acute coronary syndromes. Eur Heart J Suppl 2010;12:F19.
178. Ripley AW, Narang J, Fifi J, Bennett HL. Aspirin and clopidogrel resistance in patients requiring endovascular neurological intervention. J Neurosurg Anesthesiol 2010;22:437.
179. Kuliczkowski W, Kaczmarski J, Greif M, Polonski L, Gasior M, Serebruany V, et al. Thrombin induced aggregation and 6-months outcome in patients with diabetes and STEMI treated with primary PCI. Eur Heart J 2010;31:972.
180. Bobescu E, Radoi M, Datcu G, Dobreanu D, Donea M, Doka B, et al. Evaluation of platelets hyperactivity, hypercoagulability status and oxidative stress biomarkers and outcomes in patients with acute coronary syndromes. Eur Heart J 2010;31:971–2.
181. Fateh-Moghadam S, Mueller E, Ziemer S, Dietz R, Gawaz M, Bocksch W. Responsiveness to higher maintenance dose of dual antiplatelet therapy and its impact on stent thrombosis. Eur Heart J 2010;31:971.
182. Ko YG, Suh JW, Kim JS, Choi DH, Hong MK, Jang YS, et al. Prognostic significance of dual hyporesponsiveness to aspirin and clopidogrel measured by verifynow assay in the patients undergoing percutaneous coronary intervention. Eur Heart J 2010;31:970–1.
183. Tokgoz HC, Tanboga IH, Can MM, Bezgin T, Akgun T, Turkyilmaz E, et al. Does platelet response to clopidogrel and/or aspirin as assessed by multiplate analyser predict short and long-term outcome following coronary stenting? Eur Heart J 2010;31:967.
184. Colic M, Calija B, Babic T, Sarenac D, Ljubic M, Spasojevic B, et al. Exaggerated platelet hypo reactivity increases bleeding risk as measured by multiplate impedance aggregometry test after coronary stenting. Eur Heart J 2010;31(Suppl. 1):204.
185. Catakoglu AB, Aytekin S, Celebi H, Sener M, Kurtoglu H, Demiroglu C, et al. The influence of aspirin resistance on non-fatal coronary events following percutaneous coronary interventions. Arch Med Sci 2009;5:531–8.
186. Sobol AB, Mochecka A, Selmaj K, Loba J. Is there a relationship between aspirin responsiveness and clinical aspects of ischemic stroke? Adv Clin Exp Med 2009;18:473–9.
187. Modica A, Karlsson F, Mooe T. The impact of platelet function or C-reactive protein, on cardiovascular events after an acute myocardial infarction. Thromb J 2009;7:12. http://dx.doi.org/10.1186/1477-9560-7-12
188. Angiolillo D, Bernardo E, Capranzano P, Sabate M, Jimenez-Quevedo P, Ferreiro JL, et al. Prognostic implications of high platelet reactivity as defined by multiple agonists in diabetes mellitus patients on dual antiplatelet therapy. J Am Coll Cardiol 2009;53:A68.
189. Harrison P, Silver L, Segal H, Syed A, Mehta Z, Rothwell P. Long term prognostic value of aspirin non-responsiveness and platelet reactivity after acute vascular events: a population-base cohort study. J Thromb Haemost 2009;7(Suppl. 2):104.
190. Range G, Richard P, Chassaing S, Belle L, Thuaire C, Cazaux P, et al. Impact of low response to aspirin and/or clopidogrel in 1001 patients undergoing coronary stenting: 1-month results of the VERIFRENCHY registry. Eur Heart J 2009;30:858. http://dx.doi.org/10.1016/j.acvd.2014.03.004
191. Milicic D, Lovric D, Skoric B, Samardzic J, Gornik I, Narancic SK, et al. Effects of lower platelet aspirin and clopidogrel response on long-term outcomes in patients with acute STEMI. Eur Heart J 2009;30(Suppl. 1):193. http://dx.doi.org/10.1016/j.ijcard.2011.09.055
192. Vaduganathan M, Guthikonda S, Nure B, Siqueiros-Garcia A, Mangalpally KR, Paranilam J, et al. Point-of-care measurement of aspirin responsiveness predicts long-term clinical outcomes in patients undergoing elective percutaneous coronary intervention. Am J Cardiol 2009;104(Suppl. 1):174D. http://dx.doi.org/10.1016/j.amjcard.2009.08.501
193. Silver LE, Harrison P, Segal H, Syed A, Mehta Z, Rothwell PM. Long-term prognostic value of aspirin non-responsiveness and platelet reactivity after acute vascular events: a population-based prospective cohort study. Cerebrovasc Dis 2009;27(Suppl. 6):28.
194. Kim S, Lee DH, Lim HK, Kwon SU, Choi CG, Suh DC. Change of platelet reactivity to antiplatelet therapy after stenting procedure for cerebral artery stenosis: Verifynow antiplatelet assay before and after stenting. Neuroradiology 2009;51:S43.
195. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008;118:1705–12. http://dx.doi.org/10.1161/CIRCULATIONAHA.108.768283
196. Kaminska M, Osada J, Dabrowska M, Kloczko J, Kramkowski K, Musial WJ. The assessment of antiplatelet activity of aspirin among survivors of myocardial infarction treated with PCI in six months observation – preliminary results. Pol Prz Kardiol 2007;9:335–41.
197. Gurbel PA, Bliden KP, Navickas I, Cohen E, Tantry US. Post-coronary intervention recurrent ischemia in the presence of adequate platelet inhibition by dual antiplatelet therapy: What are we overlooking? J Thromb Haemost 2007;5:2300–1. http://dx.doi.org/10.1111/j.1538-7836.2007.02749.x
198. Stejskal D, Vaclavik J, Lacnak B, Proskova J. Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med 2006;17:349–54. http://dx.doi.org/10.1016/j.ejim.2006.01.006
199. Sambu N, Radhakrishnan A, Dent H, Calver AL, Corbett S, Gray H, et al. Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST)registry. Heart 2012;98:706–11. http://dx.doi.org/10.1136/heartjnl-2011-301164
200. Lee DH, Kim HS, Kim SM, Kwon SU, Suh DC. Change of platelet reactivity to antiplatelet therapy after stenting procedure for cerebral artery stenosis: VerifyNow antiplatelet assay before and after stenting. Neurointervention 2012;7:23–6. http://dx.doi.org/10.5469/neuroint.2012.7.1.23
201. Feng XR, Liu ML, Liu F, Tian QP, Fan Y, Liu QZ. [Aspirin response and related factors in aged patients.] Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih 2011;39:925–8.
202. Eskandarian R, Darabian M. Impact of aspirin resistance on one year’s prognosis in chronic stable angina in Semnan – Iran. Atheroscler Suppl 2011;12:170. http://dx.doi.org/10.1016/S1567-5688(11)70811-X
203. Verschuren JJ, Trompet S, Wessels JA, Guchelaar HJ, de Maat MP, Simoons ML, et al. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? Eur Heart J 2012;33:165–75. http://dx.doi.org/10.1093/eurheartj/ehr239
204. Dickinson KJ, Troxler M, Homer-Vanniasinkam S. The surgical application of point-of-care haemostasis and platelet function testing. Br J Surg 2008;95:1317–30. http://dx.doi.org/10.1002/bjs.6359
205. El-Menyar A, Hussein H, Al Suwaidi J. Coronary stent thrombosis in patients with chronic renal insufficiency. Angiology 2010;61:297–303. http://dx.doi.org/10.1177/0003319709344574
206. Velkovic J, Coulthard A. The drugs don’t work: low response to antiplatelet agents in patients undergoing endovascular procedures. J Med Imaging Radiat Oncol 2009;53:A275.
207. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, De Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008;99:14–26. http://dx.doi.org/10.1160/TH07-08-0530
208. Reny JL, de Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008;6:444–50. http://dx.doi.org/10.1111/j.1538-7836.2008.02897.x
209. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336:195–8. http://dx.doi.org/10.1136/bmj.39430.529549.BE
210. Ferguson AD, Dokainish H, Lakkis N. Aspirin and clopidogrel response variability: review of the published literature. Tex Heart Inst J 2008;35:313–20.
211. Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events – a meta-analysis. Int J Cardiol 2008;128:166–71. http://dx.doi.org/10.1016/j.ijcard.2007.12.010
212. Musallam KM, Charafeddine K, Bitar A, Khoury M, Assaad S, Beresian J, et al. Resistance to aspirin and clopidogrel therapy. Int J Lab Hematol 2011;33:1–18. http://dx.doi.org/10.1111/j.1751-553X.2010.01268.x
213. Wong S, Appleberg M, Ward CM, Lewis DR. Aspirin resistance in cardiovascular disease: a review. Eur J Vasc Endovasc Surg 2004;27:456–65. http://dx.doi.org/10.1016/j.ejvs.2003.12.025
214. Howard PA. Aspirin resistance. Ann Pharmacother 2002;36:1620–4. http://dx.doi.org/10.1345/aph.1C013
215. Canivano PL, Garcia YC. [Resistance to aspirin: prevalence, mechanisms of action and association with thromboembolic events. A narrative review.] Farm Hosp 2010;34:32–43. http://dx.doi.org/10.1016/j.farma.2009.08.002
216. Pusch G, Feher G, Kotai K, Tibold A, Gasztonyi B, Feher A, et al. Aspirin resistance: focus on clinical endpoints. J Cardiovasc Pharmacol 2008;52:475–84. http://dx.doi.org/10.1097/FJC.0b013e31818eee5f
217. Snoep JD, Hovens MM, Eikenboom JC, Van Der Bom JG, Huisman MV. Association of laboratorydefined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007;167:1593–9. http://dx.doi.org/10.1001/archinte.167.15.1593
218. Mansour K, Taher AT, Musallam KM, Alam S. Aspirin resistance. Adv Hematol 2009;2009:937352. http://dx.doi.org/10.1155/2009/937352
219. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230–5. http://dx.doi.org/10.1016/S0002-9149(01)01631-9
220. Andersen LA, Gormsen J. Platelet aggregation and fibrinolytic activity in transient cerebral ischemia. Acta Neurol Scand 1976;55:76–82. http://dx.doi.org/10.1111/j.1600-0404.1977.tb05628.x
221. Fritsma GA, Ens GE, Alvord MA, Carroll AA, Jensen R. Monitoring the antiplatelet action of aspirin. JAAPA 2001;14:57–8, 61–2.
222. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001;138:152–63. http://dx.doi.org/10.1067/mlc.2001.117406
223. Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002;9:407–15. http://dx.doi.org/10.1097/00062752-200209000-00004
224. Escolar G, Cases A, Vinas M, Pino M, Calls J, Cirera I, et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyser (PFA 100TM): Influence of hematocrit elevation. Haematologica 1999;84:614–19.
225. Borna C, Lazarowski E, van Heusden C, Ohlin H, Erlinge D. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J 2005;3:10. http://dx.doi.org/10.1186/1477-9560-3-10
226. Sathiropas P. Detection of small inhibitory effects on acetylsalicylic acid (ASA)by platelet impedance aggregometry in whole blood. Thromb Res 1988;51:55–62. http://dx.doi.org/10.1016/0049-3848(88)90282-4
227. Friend M, Vucenik I, Miller M. Platelet responsiveness to aspirin in patients with hyperlipidemia. BMJ 2003;326:82–3. http://dx.doi.org/10.1136/bmj.326.7380.82
228. Korpanty A, Ravindra S, Yassin J, Frenkel EP. Sensitivity of whole blood aggregation, platelet rich plasma, and platelet function analyzer in detection aspirin effect on platelet function. J Am Soc Hematol 2002;100:11.
229. Korpanty A, Frenkel EP, Sarode R. An approach to the assessment of platelet function: comparison of optical platelet rich and impedance whole blood aggregation methods. Thromb Hemost 2005;11:25–35. http://dx.doi.org/10.1177/107602960501100103
230. Ivandic B, Giannitis E, Schlick P, Staritz P, Katus H, Hohlfeld T. Determination of aspirin responsiveness by use of whole blood platelet aggregometry. Clin Chem 2007;53:614–19. http://dx.doi.org/10.1373/clinchem.2006.081059
231. Poston RS, White C, Gu J, Brown J, Gammie J, Pierson RN, et al. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg 2006;81:104–10. http://dx.doi.org/10.1016/j.athoracsur.2005.05.085
232. Haude M, Hafner G, Jablonka A, Rupprecht HJ, Prellwitz W, Meyer J, et al. Guidance of anticoagulation after intracoronary implantation of Palmaz-Schatz stents by monitoring prothrombin and prothrombin fragment 1. Am Heart J 1995;130:228–38. http://dx.doi.org/10.1016/0002-8703(95)90433-6
233. Grotemeyer KH. The platelet-reactivity-test – a useful ‘by-product’ of the blood-sampling procedure? Thromb Res 1991;61:423–31. http://dx.doi.org/10.1016/0049-3848(91)90656-H
234. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991;63:587–93. http://dx.doi.org/10.1016/0049-3848(91)90085-B
235. Zhang Y, Liang J, Zhou YJ, Yuan H, Zhang YZ, Dong L. [Study on the relationship between aspirin resistance and incidence of myonecrosis after non-emergent percutaneous coronary intervention.] Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih 2005;33:695–9.
236. Yilmaz MB, Balbay Y, Caldir V, Ayaz S, Guray Y, Guray U, et al. Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. Thromb Res 2005;115:25–9. http://dx.doi.org/10.1016/j.thromres.2004.07.004
237. Valles J, Santos MT, Fuset MP, Moscardo A, Ruano M, Perez F, et al. Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2007;99:19–25. http://dx.doi.org/10.1016/j.amjcard.2006.07.058
238. Malek LA, Spiewak M, Filipiak KJ, Grabowski M, Szpotanska M, Rosiak M, et al. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes. Kardiol Pol 2007;65:40–5.
239. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006;47:27–33. http://dx.doi.org/10.1016/j.jacc.2005.08.058
240. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Nurkalem Z, et al. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J Exp Med 2005;207:59–64. http://dx.doi.org/10.1620/tjem.207.59
241. Faraday N, Braunstein JB, Heldman AW, Bolton ED, Chiles KA, Gerstenblith G, et al. Prospective evaluation of the relationship between platelet–leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes. Platelets 2004;15:9–14. http://dx.doi.org/10.1080/09537100310001644006
242. Chen W-H, Lee P-Y, Ng W, Tse H-F, Lau C-P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122–6. http://dx.doi.org/10.1016/j.jacc.2003.12.034
243. Chen W-H, Lee P-Y, Ng W, Kwok JYY, Cheng X, Lee SWL, et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary Intervention. Am J Cardiol 2005;96:760–3. http://dx.doi.org/10.1016/j.amjcard.2005.04.056
244. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002;108:37–42. http://dx.doi.org/10.1016/S0049-3848(02)00405-X
245. Atiemo AD, Ng’Alla LS, Vaidya D, Williams MS. Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain. J Thromb Thrombolysis 2008;25:173–8. http://dx.doi.org/10.1007/s11239-007-0045-5
246. Berrouschot J, Schwetlick B, von Twickel G, Fischer C, Uhlemann H, Siegemund T, et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006;113:31–5. http://dx.doi.org/10.1111/j.1600-0404.2005.00419.x
247. Poston RS, Gu J, Brown JM, Gammie JS, White C, Nie L, et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2006;131:122–30. http://dx.doi.org/10.1016/j.jtcvs.2005.08.058
248. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63–6. http://dx.doi.org/10.1007/s00415-003-0954-y
249. McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 2005;16:269–80. http://dx.doi.org/10.1080/09537100400020567
250. Poulsen TS, Jørgensen B, Korsholm L, Licht PB, Haghfelt T, Mickley H. Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb Res 2007;119:555–62. http://dx.doi.org/10.1016/j.thromres.2006.04.005
251. Pamukcu B, Oflaz H, Nisanci Y. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J 2005;149:675–80. http://dx.doi.org/10.1016/j.ahj.2004.10.007
252. Linden MD, Furman MI, Frelinger AL III, Fox ML, Barnard MR, Li Y, et al. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost 2007;5:761–5. http://dx.doi.org/10.1111/j.1538-7836.2007.02462.x
253. Gulmez O, Yildirir A, Kaynar G, Konas D, Aydinalp A, Ertan C, et al. Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions. J Thromb Thrombolysis 2007;25:239–46. http://dx.doi.org/10.1007/s11239-007-0067-z
254. Cornelissen J, Kirtland S, Lim E, Goddard M, Bellm S, Sheridan K, et al. Biological efficacy of low against medium dose aspirin regimen after coronary surgery: analysis of platelet function. Thromb Haemost 2006;95:476–82.
255. Cheng X, Chen WH, Lee PY, Ng W, Kwok YY, Lau CP. Prevalence, profile, predictors, and natural history of aspirin resistance measured by the Ultegra Rapid Platelet Function Assay-ASA in patients with coronary heart disease. Circulation 2005;111:E339.
256. Geisler T, Kapp M, Gohring-Frischholz K, Daub K, Dosch C, Bigalke B, et al. Residual platelet activity is increased in clopidogrel-and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 2008;94:743–7. http://dx.doi.org/10.1136/hrt.2006.100891
257. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908–13. http://dx.doi.org/10.1161/01.CIR.0000072771.11429.83
258. ClinicalTrials.gov. Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia. URL: http://ClinicalTrials.gov/show/NCT01104441 (accessed 2 April 2012).
259. ClinicalTrials.gov. Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting. URL: http://ClinicalTrials.gov/show/NCT01159639 (accessed 2 April 2012).
260. ClinicalTrials.gov. Aspirin Responsiveness and Outcome in Coronary Artery Bypass Graft (CABG)Surgery. URL: http://ClinicalTrials.gov/show/NCT01174862 (accessed 2 April 2012).
261. ClinicalTrials.gov. Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. URL: http://ClinicalTrials.gov/show/NCT00262561 (accessed 2 April 2012).
262. ClinicalTrials.gov. The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study). URL: http://clinicaltrials.gov/ct2/show/study/NCT00250380 (accessed 2 April 2012).
263. ClinicalTrials.gov. Evaluation and Comparison of Several Point-of-Care Platelet Function Tests in Predicting Clinical Outcomes in Clopidogrel Pre-Treated Patients Undergoing Elective PCI. URL: http://ClinicalTrials.gov/show/NCT00352014 (accessed 2 April 2012).
264. ClinicalTrials.gov. Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting: The PAPA CABG Study. URL: https://clinicaltrials.gov/show/NCT00330772 (accessed 2 April 2012).
265. Reny JL, Berdague P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P, et al. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the ADRIE study. Circulation 2012;125:3201–10. http://dx.doi.org/10.1161/CIRCULATIONAHA.111.085464
266. Collet J-P, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. New Engl J Med 2012;367:2100–9. http://dx.doi.org/10.1056/NEJMoa1209979
267. Yamane K, Taniguchi R, Watanabe S, Kawato M, Shirakawa R, Higashi T, et al. Impact of platelet reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin. J Atheroscler Thromb 2012;19:1142–53. http://dx.doi.org/10.5551/jat.14100
268. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care 2005;21:240–5.
269. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006;24:355–71. http://dx.doi.org/10.2165/00019053-200624040-00006
270. Bronnum-Hansen H, Davidsen M, Thorvaldsen P. Long-term survival and causes of death after stroke. Stroke 2001;32:2131–6. http://dx.doi.org/10.1161/hs0901.094253
271. Bronnum-Hansen H, Jorgensen T, Davidsen M, Madsen M, Osler M, Gerdes LU, et al. Survival and cause of death after myocardial infarction: the Danish MONICA study. J Clin Epidemiol 2001;54:1244–50. http://dx.doi.org/10.1016/S0895-4356(01)00405-X
272. Joint Formulary Committee. British National Formulary. 65 edn. London: BMJ Group and Pharmaceutical Press; 2013.
273. Department of Health. NHS Reference Costs: Financial Year 2011 to 2012. London: Department of Health; 2012.
274. Robinson M, Palmer S, Sculpher MJ, Philips Z, Ginnelly L, Bowens A, et al. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision analytic modelling. Health Technol Assess 2005;9(27). http://dx.doi.org/10.3310/hta9270
275. Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003;21(Suppl. 1):43–50. http://dx.doi.org/10.2165/00019053-200321001-00005
276. Greenhalgh J, Bagust A, Boland A, Martin SC, Oyee J, Blundell M, et al. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technol Assess 2011;15(31). http://dx.doi.org/10.3310/hta15310
277. Cooper A, Nherera L, Calvert N, O’Flynn N, Turnbull N, Robson J, et al. Clinical Guidelines and Evidence Review for Lipid Modification: Cardiovascular Risk Assessment and the Primary and Secondary Prevention of Cardiovascular Disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008.
278. Ward S, Lloyd JM, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11(14). http://dx.doi.org/10.3310/hta11140
279. Office for National Statistics. Statistical Bulletin: Deaths Registered in England and Wales, 2012. Newport: Office for National Statistics; 2012.
280. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. Centre for Health Economics discussion paper York: Centre for Health Economics, University of York; 1999.
281. National Institute for Health and Care Excellence (NICE). The Guidelines Manual. London: NICE; 2012.
282. Lordkipanidzé M, Diodati JG, Schampaert E, Palisaitis DA, Pharand C. Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease. Am J Cardiol 2009;104:1189–93. http://dx.doi.org/10.1016/j.amjcard.2009.06.025
283. Fontana P, Nolli S, Reber G, de Moerloose P. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006;4:813–19. http://dx.doi.org/10.1111/j.1538-7836.2006.01867.x
284. Cuisset T, Frere C, Quilici J, Morange PE, Camoin L, Bali L, et al. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thromb Res 2009;123:597–603. http://dx.doi.org/10.1016/j.thromres.2008.04.003
285. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006;25:127–41. http://dx.doi.org/10.1002/sim.2331
286. Riley RD, Lambert PC, Abo G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010;340:410–14. http://dx.doi.org/10.1136/bmj.c221
287. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 1999;28:1–9. http://dx.doi.org/10.1093/ije/28.1.1
288. Altman DG, Trivella M, Pezzella F, Harris AL, Pastorino U. Systematic review of multiple studies of prognosis: the feasibility of obtaining individual patient data. In Auget J-L, Balakrishnan N, Mesbah M, Molenberghs G, editors. Advances in Statistical Methods for the Health Sciences. Boston, MA: Birkhauser; 2006. pp. 3–18.
289. Kyzas PA, Loizou KT, Ioannidis JPA. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005;97:1043–55. http://dx.doi.org/10.1093/jnci/dji184
290. Hemingway H, Riley RD, Altman DG. Ten steps towards improving prognosis research. BMJ 2009;339:b4184. http://dx.doi.org/10.1136/bmj.b4184
291. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, et al. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 2003;88:1191–8. http://dx.doi.org/10.1038/sj.bjc.6600886
292. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using ‘optimal’ cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829–35. http://dx.doi.org/10.1093/jnci/86.11.829
293. Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA, et al. Prognosis research strategy (PROGRESS)2: prognostic factor research. PLOS Med 2013;10:e1001380. http://dx.doi.org/10.1371/journal.pmed.1001380
294. Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, et al. Prognosis research strategy (PROGRESS)1: a framework for researching clinical outcomes. BMJ 2013;346:e5595. http://dx.doi.org/10.1136/bmj.e5595
295. Steyerberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, et al. Prognosis research strategy (PROGRESS)3: prognostic model research. PLOS Med 2013;10:e1001381. http://dx.doi.org/10.1371/journal.pmed.1001381
296. Hingorani AD, Windt DA, Riley RD, Abrams K, Moons KG, Steyerberg EW, et al. Prognosis research strategy (PROGRESS)4: stratified medicine research. BMJ 2013;346:e5793. http://dx.doi.org/10.1136/bmj.e5793
297. Rifai N, Altman DG, Bossuyt PM. Reporting bias in diagnostic and prognostic studies: time for action. Clin Chem 2008;54:1101–3. http://dx.doi.org/10.1373/clinchem.2008.108993
298. Simon R, Sobin LH. Evaluating prognostic factor studies. In TNM Online. John Wiley & Sons; 2003. URL: http://onlinelibrary.wiley.com/doi/10.1002/0471463736.tnmp04/abstract;jsessionid=360A7A5DF057D84D94606C0A801173E1.f02t03 (accessed 24 March 2015).
299. Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, Jones DR, et al. A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing’s sarcoma and neuroblastoma. Health Technol Assess 2003;7(5). http://dx.doi.org/10.3310/hta7050
300. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 2007;43:2559–79. http://dx.doi.org/10.1016/j.ejca.2007.08.030
301. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001;323:224–8. http://dx.doi.org/10.1136/bmj.323.7306.224
302. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005;6:678–86. http://dx.doi.org/10.1016/S1470-2045(05)70315-6
303. Hemingway H, Philipson P, Chen R, Fitzpatrick NK, Damant J, Shipley M. Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLOS Med 2010;7:e1000286. http://dx.doi.org/10.1371/journal.pmed.1000286
304. Sauerbrei W. Prognostic factors. Confusion caused by bad quality design, analysis and reporting of many studies. Adv Otorhinolaryngol 2005;62:184–200.
305. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 1998;52:289–303. http://dx.doi.org/10.1023/A:1006193704132
306. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:979–85. http://dx.doi.org/10.1038/bjc.1994.192
307. Debray TP, Moons KG, Ahmed I, Koffijberg H, Riley RD. A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis. Stat Med 2013;32:3158–80. http://dx.doi.org/10.1002/sim.5732
308. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982–90. http://dx.doi.org/10.1016/j.jclinepi.2005.02.022